Fada Medical is developing a novel drug diffusion technology that extends the lifespan of insulin infusion cannulas to 30 days, significantly reducing the frequency of changes required for insulin pump users. This advancement addresses the high failure rates and short lifespan of current infusion sets, which disrupt insulin therapy and negatively impact blood glucose control for individuals with type 1 diabetes.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current insulin infusion sets for insulin pumps typically last only 2-3 days, leading to frequent interruptions in insulin therapy. These short lifespans and high failure rates can negatively impact blood glucose control for individuals with type 1 diabetes. Failed cannulas also contribute to environmental waste and increased healthcare costs due to discarded insulin and replacement sets.
Solution
Fada Medical is developing a novel drug diffusion technology, called Ripple Tech, designed to extend the lifespan and improve the performance of insulin infusion cannulas. This technology aims to increase the wear time of cannulas to up to 30 days, significantly reducing the frequency of infusion set changes for insulin pump users. By preventing cannula occlusion and other causes of early failure, Fada Medical's technology promotes more consistent and reliable insulin delivery. The extended wear time reduces interruptions to insulin therapy, leading to better blood-glucose control and a reduced environmental impact.
Target Audience
The primary target audience includes individuals with type 1 diabetes who use insulin pumps, as well as healthcare providers and diabetes clinics focused on improving insulin delivery and glycemic control.
Features
- Novel drug diffusion technology to prevent cannula occlusion
- Extended cannula lifespan of up to 30 days
- Compatible with existing insulin pump systems
- Designed to improve the consistency and reliability of insulin delivery
- Reduces the frequency of infusion set changes